American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction
- PMID: 29452019
- PMCID: PMC2795413
- DOI: 10.1200/JOP.0948502
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction
Abstract
ASCO's update to its Clinical Practice Guideline on the use of pharmacologic interventions to reduce the risk of breast cancer addresses the roles of tamoxifen, raloxifene, aromatase inhibitors, and fenretinide in reducing risk for the disease.
References
-
- Visvanathan K, Chlebowski RT, Hurley P, et al: American Society of Clinical Oncology Clinical Practice Guideline Update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27:3235-3258, 2009 - PMC - PubMed
-
- National Cancer Institute: Breast Cancer Risk Assessment Tool. www.cancer.gov/bcrisktool
LinkOut - more resources
Full Text Sources
Other Literature Sources